Gold bars to be exempt from tariffs, White House clarifies
Zelin reiterated the Buy rating and price target for Janux Therapeutics, reflecting confidence in the company's clinical strategy and the potential of its product pipeline. According to InvestingPro, the stock currently has a highly favorable analyst consensus rating of 1.21 (where 1 is Strong Buy), with analyst targets ranging from $25 to $200.
Subscribers can access 12 additional ProTips and comprehensive financial metrics to better evaluate this volatile biotech investment. According to InvestingPro, the stock currently has a highly favorable analyst consensus rating of 1.21 (where 1 is Strong Buy), with analyst targets ranging from $25 to $200. Subscribers can access 12 additional ProTips and comprehensive financial metrics to better evaluate this volatile biotech investment.
Zelin reiterated the Buy rating and price target for Janux Therapeutics, reflecting confidence in the company's clinical strategy and the potential of its product pipeline. According to InvestingPro, the stock currently has a highly favorable analyst consensus rating of 1.21 (where 1 is Strong Buy), with analyst targets ranging from $25 to $200. Subscribers can access 12 additional ProTips and comprehensive financial metrics to better evaluate this volatile biotech investment.
The analyst pointed out that Janux is progressing with the 6 and 9mg doses of JANX007 to Phase 1b in pre-Pluvicto second/third line patients and is considering every two weeks dosing regimens greater than 3mg for convenience as a maintenance regimen after the initial two cycles of weekly treatments. Janux is also assessing a 12mg dose due to the absence of a maximum tolerated dose (MTD), and pending further data, may decide to advance this dose in clinical development.
Zelin reiterated the Buy rating and price target for Janux Therapeutics, reflecting confidence in the company's clinical strategy and the potential of its product pipeline.
In other recent news, Janux Therapeutics has been the subject of multiple analyst forecasts following promising clinical results. Clear Street initiated coverage on Janux Therapeutics with a Buy rating and a price target of $80, expressing confidence in the potential of the company's leading drug candidate, JANX007, in the oncology market.
Similarly, Scotiabank (TSX:BNS) increased its price target for Janux Therapeutics to $62 from $42, maintaining its Sector Perform rating. Jones Trading raised its price target for Janux to $105, while Stifel increased its price target to $115, both maintaining a Buy rating.
TD Cowen reiterated a Buy rating on Janux Therapeutics, highlighting the impressive results of the company's '007 candidate in reducing prostate-specific antigen levels. These recent developments suggest that '007 could become the preferred non-androgen therapy for metastatic castration-resistant prostate cancer, with the potential to generate multiple billions in revenue.
The analysts' expectations are now looking forward to the results from the expansion portion of the trial, which are anticipated in 2025. These updates, according to Stifel, are not currently factored into their or investors' valuations, suggesting that positive results could lead to additional positive revisions in the future.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.